Drug intelligence / Profile preview

Amladex

Development stage: Unknown
Lead developer: Misemer Pharmaceutical
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

**Amladex** is a prescription-dispensed oral dietary vitamin supplement from Misemer Pharmaceutical for clinical dietary management of suboptimal nutritional status when advanced folate supplementation and nutritional support during physiologically stressful conditions are needed. Each tablet combines ascorbic acid, cholecalciferol, thiamine, pyridoxal phosphate, folic acid, methylcobalamin, reduced nicotinamide adenine dinucleotide, and ubiquinone. It is supplied as a coated tablet and is intended for use under supervision of a licensed medical practitioner. ([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5c0a8d16-49db-434d-9aeb-9e694d25e5c0))

Brand names: Amladex

Beyond the preview

Go deeper on Amladex.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amladex.

Explore the full profile